Neurovive Pharmaceutical AB, of Lund, Sweden, disclosed results from the exploratory phase II study CiPRICS, showing that patients treated with its Ciclomulsion prior to open heart surgery experienced no benefit compared to placebo in the prevention of acute kidney injury.